Principal Investigator: Professor Lorcan McGarvey
Name of the Study: Bellus BUS P2-02 (Soothe)
Why is this Study important? Despite being common, there are currently no approved treatments for RCC. RCC has significant psychological, social and physical impacts which affect people with this condition on a daily basis.
What is the Research question/aim? This Phase 2b study aims to demonstrate the safety and efficacy of multiple doses of a compound called BLU-5937 in adults suffering from refractory chronic cough (RCC).
What the Study involves: The study will evaluate 3 active doses of the BLU-5937 compound plus a placebo dose. Once study eligibility has been ascertained, 240 participants from across the UK, Europe, USA and Canada will be randomly assigned to receive one of these 4 treatment arms on a 1:1:1:1 ratio.
There will be a total of 8 study visits over a 3 month period, most of these will take place in the hospital but some of the visits may be able to take place in the participant’s home.
Visits are expected to take approximately 1-4 hours, and unscheduled visits may be planned if necessary.
Who can take part in the Study?
People with refractory chronic cough (RCC) who meet inclusion/exclusion criteria for the study. Contact study team for more information.
Clinical Research Nurse